An observational study in Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP) and Eczema Atopic Dermatitis, sponsored by AI Labs Group S.L. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by AI Labs Group S.L · Observational
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions. Dermatological issues are common in primary care, but there is often a gap in diagnostic accuracy between general practitioners and specialists, which can lead to treatment delays for serious conditions like Generalized Pustular Psoriasis (GPP) and Hidradenitis Suppurativa (HS).
The researchers hypothesized that the AI device would enhance the diagnostic accuracy of healthcare professionals for GPP and other dermatological conditions. To test this, the study followed a prospective observational design involving 15 practitioners, including both general practitioners and dermatologists.
During the study, participants were asked to evaluate 100 clinical images. For each case, they first provided a diagnosis based on the image and patient history alone. They were then shown the AI's analysis-which included the top five suggested diagnoses and confidence levels-and asked if they would like to adjust their initial assessment.
The primary question the study sought to answer was whether the information provided by the AI device could significantly increase the number of correct diagnoses made by these professionals, particularly for rare diseases that are often difficult to identify in a standard clinical setting
This investigation is structured as a multi-reader multi-case (MRMC) study. A cohort of 15 healthcare professionals, including 11 primary care physicians and 4 dermatologists, acted as the "readers". These readers evaluated a "case" set of 100 clinical images to assess diagnostic performance both with and without the assistance of the AI device.
Study Design and Technical Methodology The research was conducted as a prospective observational and cross-sectional study. It utilized a "physician-as-their-own-control" design to measure the impact of Artificial Intelligence (AI) on diagnostic performance.
Quality Assurance and Data Management
To ensure the scientific integrity and reliability of the findings, several quality control measures were implemented:
Statistical Analysis Plan
The primary goal of the analysis was to quantify Top-1 accuracy, sensitivity, and specificity for both general practitioners and dermatologists.
Ethical and Confidentiality Framework The study adhered to UNE-EN ISO 14155:2021, the Declaration of Helsinki, and the General Data Protection Regulation (GDPR).
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's enrollment of 15 is below the median of 199 across 407 observational studies indexed under Psoriasis.
Browse Psoriasis studies →AI Labs Group S.L is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of board-certified healthcare professionals recruited from the clinical fields of general medicine and dermatology. The participant group includes:
Participants were recruited to engage in a remote, web-based evaluation environment rather than being selected from a single physical hospital or town. The clinical images evaluated as part of the study "cases" were sourced from international public dermatology atlases and existing research databases from the sponsor, representing a diverse global patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group is composed of board-certified healthcare professionals (HCPs) who serve as the "readers" in this multi-reader multi-case (MRMC) study. The cohort is uniquely characterized by its internal comparison: each participant acts as their own control. * Dual Professional Roles: The group includes 11 primary care physicians (PCPs) and 4 dermatologists, allowing for a comparison between generalist and specialist diagnostic baseline performance. * Interventional Exposure: All participants are evaluated under two distinct conditions: first, providing a diagnosis based solely on clinical images and patient history; second, providing a diagnosis assisted by the AI-based medical device's top 5 suggestions and confidence levels. * Clinical Expertise: Every member of the cohort has a minimum of 5 years of clinical experience in their respective field.
Device: AI-based medical device for aided diagnosis in Dermatology
The intervention consists of a Computer-Aided Diagnosis (CAD) software-only medical device that utilizes computer vision algorithms to analyze digital images of skin structures. During the study, healthcare professionals use the tool as a diagnostic support system to assist in the evaluation of complex dermatological conditions.
Diagnostic Accuracy for Generalized Pustular Psoriasis (GPP) with and without Artificial Intelligence Support.
This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying GPP. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.
Time frame: Day 1
Diagnostic Accuracy for different skin conditions with and without Artificial Intelligence Support
This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying the corresponding skin condition. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.
Time frame: Day 1
Diagnostic Accuracy for Rare Dermatological Conditions with and without Artificial Intelligence Support.
This measure evaluates the Top-1 diagnostic accuracy of healthcare professionals (HCPs) when identifying rare dermatological conditions. Accuracy is calculated by comparing the clinician's diagnosis (both with and without the device's top 5 suggestions) against the confirmed reference diagnosis for each of the clinical cases.
Time frame: Day 1
Plan to share: No
Ran from Jun 2024 to primary completion in Sep 2024, 3 months.
Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's 3 months is below that.
Counting every sponsor, half of 173 studies reached it within 37 months; a quarter within 23 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AI Labs Group S.L